---
title: "AstraZeneca (AZN) was upgraded to a Hold Rating at Deutsche Bank"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299013676.md"
description: "AstraZeneca received a Hold rating and an £117.00 price target from Deutsche Bank analyst Emmanuel Papadakis today. Papadakis covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and Sanofi. According to TipRanks, Papadakis has an average return of 4.1% and a 52.45% success rate on recommended stocks. In addition to Deutsche Bank , AstraZeneca also received a Hold from HSBC’s Rajesh Kumar in a report issued on September 10. However, yesterday, Berenberg Bank maintained a Buy rating on AstraZeneca (LSE: AZN)."
datetime: "2026-09-15T07:35:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299013676.md)
  - [en](https://longbridge.com/en/news/299013676.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299013676.md)
generator: "portal-rs"
---

# AstraZeneca (AZN) was upgraded to a Hold Rating at Deutsche Bank

AstraZeneca received a Hold rating and an £117.00 price target from Deutsche Bank analyst Emmanuel Papadakis today.

Papadakis covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and Sanofi. According to TipRanks, Papadakis has an average return of 4.1% and a 52.45% success rate on recommended stocks. 

In addition to Deutsche Bank , AstraZeneca also received a Hold from HSBC’s Rajesh Kumar in a report issued on September 10. However, yesterday, Berenberg Bank maintained a Buy rating on AstraZeneca (LSE: AZN).

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)
- [HSBC.US](https://longbridge.com/en/quote/HSBC.US.md)
- [HSBH.US](https://longbridge.com/en/quote/HSBH.US.md)
- [HSBA.UK](https://longbridge.com/en/quote/HSBA.UK.md)
- [DB.US](https://longbridge.com/en/quote/DB.US.md)
- [DBK.DE](https://longbridge.com/en/quote/DBK.DE.md)
- [GSK.US](https://longbridge.com/en/quote/GSK.US.md)
- [SNY.US](https://longbridge.com/en/quote/SNY.US.md)
- [03KB.DE](https://longbridge.com/en/quote/03KB.DE.md)
- [DPB.DE](https://longbridge.com/en/quote/DPB.DE.md)
- [GSK.UK](https://longbridge.com/en/quote/GSK.UK.md)
- [GSK.WI.US](https://longbridge.com/en/quote/GSK.WI.US.md)
- [SNYNF.US](https://longbridge.com/en/quote/SNYNF.US.md)
- [DTIW.SG](https://longbridge.com/en/quote/DTIW.SG.md)
- [00005.HK](https://longbridge.com/en/quote/00005.HK.md)

## Related News & Research

- [5-AstraZeneca CEO strikes bullish tone on pipeline as stock rallies](https://longbridge.com/en/news/303770251.md)
- [AstraZeneca Q3 2026 reported EPS rises 23% to $2.02](https://longbridge.com/en/news/303734456.md)
- [AstraZeneca Projects $80 Bln In Total Revenue By 2030, Sustained Growth Beyond](https://longbridge.com/en/news/303182515.md)
- [AstraZeneca Publishes Clinical Trials Pipeline Presentation](https://longbridge.com/en/news/303693696.md)
- [AstraZeneca Readies New Portfolio of Targeted Cancer Therapies](https://longbridge.com/en/news/303003559.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**